Next generation cancer immunotherapy: targeting the tumour microenvironment

Despite advances in immunotherapies, obstacles and challenges, including limited response rates, the inability to predict clinical efficacy, and potential side effects such as autoimmune reactions or cytokine release syndromes, remain and hinder further applications of immunotherapies in clinics. Thus, a deeper understanding of the TME, able to dissect distinct classes and subclasses of it, is essential for deciphering new mechanisms of immunotherapies, defining new predictive biomarkers, and dentifying novel therapeutic targets.

See the call on Tanscan-2s website.

Messages at time of print 2 October 2023, 09:37 CEST

No global messages displayed at time of print.